Health Canada has approved the enzyme replacement therapy Elfabrio (pegunigalsidase alfa) to treat adults with Fabry disease. “With Health Canada’s approval of Elfabrio, we’re proud to have a new treatment option available to Canadians living with Fabry disease,” John Hess, senior vice president for the Americas at…
News
Young adults with Fabry disease in Canada are at a significantly higher risk of experiencing a first-time stroke or transient ischemic attack (temporary blockages sometimes referred to as “mini-strokes”) than the general population, a new study reveals. Despite this elevated risk, very few Fabry patients who experienced a first…
A one-time infusion of gene therapy ST-920 (isaralgagene civaparvovec) improved kidney function and stabilized heart function in adults with Fabry disease for up to two years after treatment, according to new data from a Phase 1/2 clinical trial. Kidney functional improvements in the…
Noninvasive echocardiogram imaging may serve as an early marker for left ventricular hypertrophy (LVH), a disease of the left heart muscle, in adults with Fabry disease, a study suggests. Imaging measurements could reliably distinguish Fabry patients among individuals with LVH, with Fabry men, in particular, showing markedly worse…
In what researchers say is the first reported case of its kind, a woman in China in her 60s was diagnosed with two co-occurring rare conditions: Fabry disease and myelodysplastic syndrome, known as MDS, a disorder in which a person’s bone marrow doesn’t make enough healthy blood cells. The…
Chiesi Global Rare Diseases and Protalix Biotherapeutics are asking a committee of the European Medicines Agency (EMA) to reconsider its recent rejection of a monthly dosing plan for their approved treatment, Elfabrio (pegunigalsidase alfa), for Fabry disease. The proposed regimen would provide patients with a more…
Enzyme replacement therapy (ERT) preserved or improved heart function in two men with Fabry disease who had already experienced kidney failure and were undergoing renal replacement (dialysis or kidney transplant), a new case study reports. The study provides evidence that ERT, the standard treatment for Fabry disease,…
The European Medicines Agency (EMA) has issued a negative opinion on a request to approve a less frequent and higher-dose regimen of Elfabrio (pegunigalsidase alfa), an approved enzyme replacement therapy (ERT) for adults with Fabry disease. The request, submitted by Elfabrio’s developers, Chiesi Global Rare Diseases and Protalix…
Noninvasive in vivo confocal microscopy (IVCM) detected signs of nerve damage in the cornea — the eye’s transparent outer layer — in people with Fabry disease, who also had higher levels of inflammatory immune cells in the cornea than healthy individuals, a study found. “IVCM provides parameters that reliably…
Long-term use of the approved oral therapy Galafold (migalastat) can help stabilize heart and kidney function in women and girls with Fabry disease across different disease severity levels, a new study from U.S. and European researchers reports. Nearly three-quarters of the female participants in the two clinical trials…
Recent Posts
- Canada approves ERT Elfabrio for adults with Fabry disease
- I work hard to influence my health outcome with Fabry disease
- Canadian study highlights stroke danger for young adults with Fabry
- Fabry treatment ST-920 boosts kidney, heart function in trial
- Echocardiograms may spot early heart disease in Fabry, study finds
- In rare case, woman diagnosed with both Fabry and blood disorder
- Companies challenge EMA advice rejecting monthly Elfabrio dosing
- ERT may protect heart function after Fabry kidney failure
- Helping my children with Fabry find ways to combat depression
- EU agency urges against monthly dosing plan for Fabry drug Elfabrio